深圳宝安福海街道作为千亿级工业重镇，正在引领中国制造从低价竞争向品质与品牌升级转变。1 该街道通过精准政策支持和优化营商环境，帮助辖区企业实现从代工供货到自主品牌的转变。1 2026年1至9月，福海街道规上工业总产值突破1364亿元。1
西昊家具有限公司是这一转型的典型代表。1 该公司从2017年开始战略性出海，2018年登陆亚马逊美国站，其M18产品一个月内售罄，前六个月卖出八千多张。1 西昊砍掉近七成低端业务，锚定"高质中高价"赛道，高端款C300国内定价三千元档，海外售价400至500美元。1 目前西昊在全国铺设近300家体验门店，海外首家专卖店落户菲律宾马尼拉，计划在东南亚落地20余家门店。1 该公司年投研发销售额的13%-16%，拥有270多项专利，年销150万件，连续四年稳居行业头部梯队。1
普博医疗技术有限公司同样实现了技术创新的突破。1 公司在深圳、瑞典、新加坡、意大利和加拿大布局五大研发中心，其高端智能呼吸机Padus 9实现了无创连续跨肺驱动压监测等核心技术突破。1 2025年普博Padus系列呼吸机及麻醉机取得沙特MDMA准入证书，截至2026年9月海外市场营收达1.2亿元。1 10月8日，飞利浦与普博医疗及其子公司达元医疗签署战略协议，普博成为飞利浦监护产品在中国大陆地区的独家战略合作伙伴。1
福海街道的产业转型成效显著。1 2026年1至9月技改投资增速达14.98%，规上服务业营收突破126亿元，其中营利性服务业营收44.2亿元，增速12.3%，工业正增长面达57.7%。1
Baoan District's Fuhai Subdistrict, a manufacturing powerhouse in Shenzhen, is steering enterprises away from low-cost competition toward premium positioning and brand recognition, demonstrating how Chinese manufacturers are upgrading their global competitiveness.1 In the first nine months of 2026, the subdistrict achieved industrial output exceeding 136.4 billion yuan, with 57.7 percent of enterprises registering positive growth.1
Two major local companies exemplify this transformation. Xiaohe Furniture initiated its international expansion strategy in 2017, launching on Amazon's U.S. platform in 2018 with its M18 model selling out within a month and generating more than 8,000 units in sales during the initial six months.1 The company has since eliminated nearly 70 percent of its low-end product lines, focusing instead on the premium segment where its C300 model commands 3,000 yuan domestically and retails for 400 to 500 U.S. dollars overseas.1 The company now operates nearly 300 experience stores nationwide, opened its first overseas flagship store in Manila, Philippines, and plans to establish over 20 additional locations across Southeast Asia.1 With annual research and development investment comprising 13 to 16 percent of sales revenue, Xiaohe holds more than 270 patents and sells 1.5 million units annually, maintaining its position among the industry's top tier for four consecutive years.1
Pubo Medical Technology has similarly scaled its ambitions by establishing five research centers across Shenzhen, Sweden, Singapore, Italy, and Canada.1 The company's flagship ventilator, the Padus 9, achieved a technological breakthrough in non-invasive continuous transpulmonary pressure gradient monitoring.1 Following approval by Saudi authorities in 2025, Padus ventilators and anesthesia machines generated 120 million yuan in overseas revenue by September 2026.1 In October, Philips formalized a strategic partnership with Pubo and its subsidiary Dayuan Medical, making Pubo the exclusive strategic partner for Philips' monitoring products in mainland China.1
The subdistrict's economic momentum extends beyond these flagship enterprises. Technology-related investments increased 14.98 percent, while service sector revenue surpassed 126 billion yuan, with profit-generating services contributing 44.2 billion yuan and expanding at 12.3 percent annually.1
评论
还没有评论，欢迎留下第一条。